Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER1 | P34995 | 1/20 | 0.57 |
| ▸ | TSHR | P16473 | 3/20 | 0.50 |
| ▸ | NPC1 | O15118 | 3/20 | 0.50 |
| ▸ | HPGD | P15428 | 2/20 | 0.50 |
| ▸ | RAB9A | P51151 | 2/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.49 |
| ▸ | DRD4 | P21917 | 1/20 | 0.47 |
| ▸ | CASP3 | P42574 | 1/20 | 0.46 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.46 |
| ▸ | CNR2 | P34972 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24252895 | 0.82 | DRD4 (0.47) | PTGER1TSHRNPC1HPGDRAB9A | |
| SCHEMBL30452353 | 0.82 | DRD4 (0.47) | PTGER1TSHRNPC1HPGDRAB9A | |
| SCHEMBL2278307 | 0.82 | KMT2A (0.48) | HPGDALDH1A1KDM4EMAPTSCN9A | |
| SCHEMBL4015350 | 0.80 | PTGER4 (0.56) | PTGER1NPC1RAB9AALDH1A1KDM4E | |
| SCHEMBL13125277 | 0.80 | NPC1 (0.56) | PTGER1TSHRNPC1HPGDRAB9A | |
| SCHEMBL18585229 | 0.80 | MAPT (0.48) | PTGER1TSHRNPC1HPGDRAB9A | |
| SCHEMBL1197051 | 0.78 | PTGER1 (0.46) | PTGER1TSHRNPC1HPGDRAB9A | |
| SCHEMBL9622761 | 0.77 | PRKAB2 (0.43) | PTGER1NPC1RAB9AALDH1A1HSD17B10 | |
| SCHEMBL1197111 | 0.77 | PTGER1 (0.45) | PTGER1TSHRNPC1HPGDRAB9A | |
| SCHEMBL8296597 | 0.76 | MEN1 (0.51) | PTGER1TSHRNPC1HPGDRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2011027156-A1 | BENZODIAZEPINE DERIVATIVES FOR TREATING HEPATITIS C INFECTION | ARROW THERAPEUTICS LIMITED (GB) | 2011-03-10 | — | — | WO | disclosed |
| US-20110059043-A1 | CHEMICAL COMPOUNDS | ARROW THERAPEUTICS LIMITED (GB) | 2011-03-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110059043-A1 | CHEMICAL COMPOUNDS | CYP2E1, CNR1, CYP3A5 | PTGER1 505/4885TSHR 598/4885NPC1 316/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.